GSE157769
RNA sequencing of tumors from PPM1D transgenic mouse model
The majority of cancers harbor alterations of the tumor suppressor TP53. However, childhood cancers, including unfavorable neuroblastoma, often lack TP53 mutations despite frequent loss of p53 function, suggesting alternative p53 inactivating mechanisms. Our study show that frequent gain of the p53-regulating gene PPM1D at chromosome 17q22.3 is linked to aggressive tumors and poor prognosis in neuroblastoma. A PPM1D transgenic mouse model develops cancers phenotypically and genetically similar to tumors arising in mice with dysfunctional p53 when subjected to low-dose irradiation. Tumors include T-cell lymphomas harboring Notch1- and Pten-mutations, adenocarcinomas and PHOX2B-expressing neuroblastomas, therey establishing PPM1D as a bona fide oncogene in wtTP53 cancer and childhood neuroblastoma. Pharmacological inhibition of WIP1 suppressed the growth of neural tumors in nude mice, proposing WIP1 as a therapeutic target in neural childhood tumors.  Overall design: Transgenic mice overexpressing PPM1D were subject to low-dose radiation and subsequently developed thymic lymphomas. Bulk RNA sequencing was performed on a total of 24 samples from 24 mice: 14 thymic lymphomas and 10 controls (thymic tissue from healthy mice). Controls were divided into four groups based on irradiation status and genotype: wild-type non-irradiated (n = 3), PPM1D-transgenic non-irradiated (n = 3), wild-type irradiated (n = 2), PPM1D-transgenic irradiated (n = 2). mRNA libraries were generated using the TruSeq Stranded cDNA kit (Illumina) and sequenced on the HiSeq 2500 platform for paired-end reads with a length of 100-125 bp for all samples.